ZYDUS LIFESCIENCES LTD
Latest filings
Next results: Wed, 4 Nov · Financial Results- Zydus Lifesciences sets Q2 FY27 results and earnings call for November 4 · Board & Shareholder Meetings
- Zydus subsidiary Zylidac Bio partners with Prolific Machines for biologics manufacturing · Compliance
- US FDA approves Zydus menopause patch with 180-day exclusivity · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹28,592 Cr over the trailing twelve months.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from ZYDUS LIFESCIENCES LTD's filed financials and exchange disclosures
What does ZYDUS LIFESCIENCES LTD do?
ZYDUS LIFESCIENCES LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol ZYDUSLIFE.
Is ZYDUS LIFESCIENCES LTD profitable?
Yes. Over the trailing twelve months ZYDUS LIFESCIENCES LTD reported a net profit of ₹4,593 Cr on revenue of ₹28,592 Cr.
Does ZYDUS LIFESCIENCES LTD pay a dividend?
Yes. The dividend yield is 0.94% at the current price. It paid out 22% of its profit as dividend in FY26.
Is ZYDUS LIFESCIENCES LTD debt-free?
No. It reported borrowings of ₹11,770 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹10,914 Cr after cash. Debt stands at 0.40× equity. That is higher than 74% of its 166 Pharmaceuticals peers.
Is ZYDUS LIFESCIENCES LTD expensive compared with its peers?
On trailing P/E, ZYDUS LIFESCIENCES LTD ranks 66 of 158 in Pharmaceuticals — cheaper than 59% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the ZYDUS LIFESCIENCES LTD share price move in a day?
On a typical session ZYDUS LIFESCIENCES LTD moves 0.84% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
When are ZYDUS LIFESCIENCES LTD's next results?
Financial Results on Wed, 4 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track ZYDUS LIFESCIENCES LTD's announcements?
Every NSE and BSE filing by ZYDUS LIFESCIENCES LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.